乳腺放射相关血管肉瘤的MRI临床价值
回顾性纳入25例乳腺放射相关血管肉瘤患者,评估MRI在诊断时及新辅助治疗后判断病变范围的价值,并与临床检查和病理对照。基线MRI与临床评估一致性中等,17%改变了手术方案;新辅助后MRI与病理一致性有限,常高估残留病变。
要点
- 基线MRI发现临床查体未识别的额外病灶,可能改变手术范围。
- 新辅助治疗后MRI常高估残留病变,解读需谨慎。
- 基线MRI与临床范围一致性仅为中等,不能替代临床检查。
核心结论
- MRI在评估乳腺放射相关血管肉瘤病变范围方面具有临床价值,可能显著改变手术方案。
- 在这组小样本队列中,新辅助治疗后MRI的额外临床价值有限。
研究设计与样本
- IRB批准的回顾性研究,纳入1995至2020年间25例有乳腺MRI的乳腺放射相关血管肉瘤患者。
- 将MRI评估的病变范围与临床检查和手术病理进行对照。
- 使用Cohen's Kappa统计评估MRI与临床评估之间的一致性。
关键影像表现/征象
- 基线MRI发现5/24(21%)患者存在初次临床检查未识别的额外病变。
- 基线MRI与临床检查病变范围一致性为中等,Cohen's κ = 0.44,95% CI 0.14-0.75。
- 13/24(54%)的MRI与临床检查一致,4/24(17%)低估病变,5/24(21%)高估病变。
- 新辅助治疗后MRI在10例患者中,4例(40%)与病理范围一致,5例(50%)高估,1例(10%)低估。
诊断标准与关键数值
- 直接手术的8例患者中,6例(75%)基线MRI范围与病理一致。
- 基线MRI改变4/24(17%)患者的手术处理方案。
临床应用与阅片要点
- 乳腺放射相关血管肉瘤患者术前行基线MRI有助于发现临床查体遗漏的病变,辅助手术规划。
- 新辅助治疗后MRI高估残留病变风险较高,报告时不宜单独据此扩大手术范围。
局限性
- 回顾性设计且样本量较小。
- 时间跨度较长(1995至2020年),检查技术和治疗方案可能不统一。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the clinical value of breast MRI in radiation-associated angiosarcoma of the breast (RAASB) for assessing disease extent at diagnosis and after neoadjuvant therapy compared with clinical examination and surgical pathology.
METHODS: This IRB-approved retrospective study included 25 patients with breast MRIs between1995 to 2020. MRI estimated disease extent was compared to clinical exam and surgical pathology. MRI findings were evaluated for additional disease and impact on clinical management. Agreement between MRI and clinical assessment of disease was evaluated using Cohen's Kappa statistic.
RESULTS: Baseline MRI demonstrated moderate agreement with clinical disease extent (Cohen's κ = 0.44, 95% CI 0.14-0.75). 13/24 (54%) of MRIs reflected clinical exam, 4/24 (17%) MRIs underestimated disease, and 5/24 (21%) MRIs overestimated disease. Baseline MRI changed surgical management in 4/24 (17%). In 8 patients that proceeded directly to surgery, MRI reflected pathology in 6/8 (75%). In 10 patients with post-neoadjuvant MRI, 4/10 (40%) pathology and MRI extent were similar, 5/10 (50%) MRI overestimated disease, and 1/10 (10%) MRI underestimated disease.
CONCLUSION: MRI has clinical value in assessing RAASB with the potential for significantly altering surgical management. In this small cohort, post-neoadjuvant MRI demonstrated limited additional clinical value. Larger studies are needed to define the optimal role and timing of post-neoadjuvant MRI.
ADVANCES IN KNOWLEDGE: Baseline MRI detected additional disease not identified on initial clinical exam in 5/24 (21%) and changed surgical management in 4/24 (17%). Although baseline MRI demonstrated moderate agreement with clinical examination, post-neoadjuvant MRI frequently overestimated residual disease when compared with final pathology.
引用
- Sae-Kho, Gonzalez, Glazebrook, et al. Clinical Value of MRI in Radiation-Associated Angiosarcoma of the Breast: Assessment of Baseline and Post-Neoadjuvant Disease. Br J Radiol. 2026. PMID: 42610719. doi:10.1093/bjr/tqag191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。